{"name":"Genus plc","slug":"genus","ticker":"GNS","exchange":"LSE","domain":"genusplc.com","description":"Genus plc is a British-based business selling elite genetics and other products manufactured using biotechnology to cattle and pig farmers. It is headquartered in Basingstoke and is a constituent of the FTSE 250 Index.","hq":"Basingstoke, UK","founded":1997,"employees":"445","ceo":"Jorgen Kokke","sector":"Animal Genetics & Biotechnology","stockPrice":0.4,"stockChange":-0.02,"stockChangePercent":-4.76,"marketCap":"$64M","metrics":{"revenue":700000000,"revenueGrowth":0,"grossMargin":32.7,"rdSpend":0,"netIncome":-55799288,"cash":2468490,"dividendYield":0,"peRatio":-10,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Genus plc Announces Strong Half-Year Results","summary":"Genus reported a 12% increase in revenue and a 15% increase in underlying profit before tax for the six months ended 31 January 2024.","drugName":"","sentiment":"positive"},{"date":"2023-09-28","type":"deal","headline":"Genus plc Acquires Remaining Stake in ABS Global","summary":"Genus completed the acquisition of the remaining 50% stake in ABS Global, a leading bovine genetics company.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-06","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-04-01","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-09","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-09","type":"earnings","source":"SEC EDGAR","summary":"20-F filed with SEC: 20-F","headline":"Annual Report (20-F) Filed","sentiment":"neutral"},{"date":"2026-02-19","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-06","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQeV9DcHpOMzdpUHhQYjRybzB3aFZUWUVnRXh4MXlOYjd6ZjcxQjN5QkY5elFEcm1OdGw1TXdLQkJtbzZENU5rUE1WT200R3d1aUpxZHdYS3RmQXVmYW5seFhybEhGbmRhUGpxQktFTHRYZWNjS2RsWVZmR3RvWHZ6T2VPSkNVMnczbl9hZ1A3Q2x1YU16SmFoWUhiSDhqcXUtUDF2NGpRMEZpWXdabl8tSVdpeDRKSkN1ODNNVUJhU3gxZWp5cURiUjhUS0RqSlJQd3dmTWhaQ1Brd9IB3wFBVV95cUxNb0staUU4WjlFM1NiY0tUa2J0ZUFHTXpKMjF4TEtoUzVzZ1dtVUZXaVFEX3M0cTJEcFJBZHhISk5nbFE0ZkdMeDV6ZGhINmwxY0F1T2pJc2VETDdCTE1MOHY2SklwMng1TE5hT05adTlha21ncmdxWGdIUmhuZWlpSm9CeHAwTENFU3kyd2FkcU4zaGNySGNnTVF0S09halJ2RHFtaGtxczZuWDRlNDltUmJ1Ul9zVU9PV0xPQmFXWGlXZ3llQ0FEQ0x6dkFBdzh3MDZYejNhbVE5a3FFRkdJ?oc=5","date":"2026-01-27","type":"pipeline","source":"simplywall.st","summary":"Investing in Genus (LON:GNS) a year ago would have delivered you a 67% gain - simplywall.st","headline":"Investing in Genus (LON:GNS) a year ago would have delivered you a 67% gain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOUGxaQmN6UU1BemhPdVVyTkVLSUVQbnNDYVVYVXREZ0RVWHJiS21YZ0NGblhJU3FkbTZzanJPaFVQUlhyOWFzdE5KVEJzYTd6MnlhenJZWjB0dmhTSVNGN3BjRUttdUNGMXJET0Y2YUZPSXRSTTlMSHhHazNuc3E1RllsX3ZoS2podDlXWGpMaU1QcVV4QTZUOG0waFVORTI0cEVNbDRUa0lvX2lsSFQ3MUhnZkpYRXBBRjdKZw?oc=5","date":"2026-01-20","type":"pipeline","source":"Proactive Investors","summary":"Genus growth prospects look healthy, says broker - Proactive Investors","headline":"Genus growth prospects look healthy, says broker","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxNOWhVYlFycTRWOVpCMllqNklJemttQ2RFRGFHQTdab2J0X3UzRU8xdWdJMnFyV0hvUDc4UkZHdmFVRXlMMHRmckZJaTcwLURVRlpYNmZ3Y3E1VlpkTE9fSUlDR1d1djJ0YkNCclItdkU0M1J2b0VzVUxtN19QeVhRNjQtUnJ5UGptRXN6RTl3anVIWk90QXF5ZmEtbHVXdm9LV3FUa3JKLXRfQUxiS0tGTzZZUVFId2ZhcE1QVlYwZmFyb01rVGZ1cng1YnE2OTBOVlRLSFBMcFYtSjIyWmtsdDRIREdub1FqSnpqemphOVNPQQ?oc=5","date":"2026-01-16","type":"pipeline","source":"Proactive Investors","summary":"Genus extends Friday rally as brokers lift forecasts after ahead-of-expectations update - Proactive Investors","headline":"Genus extends Friday rally as brokers lift forecasts after ahead-of-expectations update","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-12","type":"regulatory","source":"simplywall.st","summary":"Institutional investors may overlook Genus plc's (LON:GNS) recent UK£60m market cap drop as long-term gains remain positive - simplywall.st","headline":"Institutional investors may overlook Genus plc's (LON:GNS) recent UK£60m market cap drop as long-term gains remain posit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNaGhCX3VXWjJaczNrN0plT0djaHVwM3hyTTljY095a2pBMzl2eEhtOHlwUTQwTUV6UzZreU5tZmpGUWw4S1RHRkdJZjJFMUV6VXp6NDcxU2xvVDlzVXdpT3M4QVZjaEdnUUJneklfUndham9DUU4wZnRlQmxYdkZxSGU1b2N1TUIwR01VTE5ON2VCalkySFdPa0YzMDlwVGJXTS1kZk5wcF9fUWxaaXA1SXBUUlpuSjhKTzVUcjVMRExJYVlMcy1LWENLaldxWHV5Y0FDREJBR051WGF3Y0ljXw?oc=5","date":"2025-11-19","type":"earnings","source":"Proactive Investors","summary":"Genus boosts shares by raising profit outlook after strong China pig sales | LSE:GNS - Proactive Investors","headline":"Genus boosts shares by raising profit outlook after strong China pig sales | LSE:GNS","sentiment":"positive"},{"date":"2025-11-17","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-15","type":"pipeline","source":"simplywall.st","summary":"Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price - simplywall.st","headline":"Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price","sentiment":"neutral"},{"date":"2025-11-10","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-10-22","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Neogen Corporation","Zoetis Inc.","Elanco Animal Health Incorporated"],"therapeuticFocus":["Animal Genetics","Livestock Biotechnology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":445,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.4,"previousClose":0.42,"fiftyTwoWeekHigh":1.92,"fiftyTwoWeekLow":0.22,"fiftyTwoWeekRange":"0.222 - 1.92","fiftyDayAverage":0.41,"twoHundredDayAverage":0.77,"beta":10.76,"enterpriseValue":99661888,"forwardPE":-10,"priceToBook":0.71,"priceToSales":7.59,"enterpriseToRevenue":11.88,"enterpriseToEbitda":-4.05,"pegRatio":0,"ebitda":-24619852,"ebitdaMargin":-293.5,"freeCashflow":12474326,"operatingCashflow":-10646554,"totalDebt":27634840,"debtToEquity":28.6,"currentRatio":0.86,"returnOnAssets":-14.1,"returnOnEquity":-63.6,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":3.25,"targetHighPrice":3.25,"targetLowPrice":3.25,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":12.1,"institutionHeldPercent":0.7,"sharesOutstanding":159839164,"floatShares":140489035,"sharesShort":2568835,"shortRatio":3.04,"shortPercentOfFloat":1.6,"epsTrailing":-0.55,"epsForward":-0.04,"revenuePerShare":0.08,"bookValue":0.56,"officers":[{"age":54,"name":"Mr. Roger James  Hamilton","title":"Founder, CEO & Director"},{"age":39,"name":"Mr. Suraj  Naik","title":"CTO & Executive Director"},{"age":34,"name":"Mr. Gaurav  Dama","title":"Chief Financial Officer"},{"age":null,"name":"Ms. Jennifer  Brady","title":"Head of Digital Marketing & Sales"},{"age":39,"name":"Ms. Eva Maria Mantziou","title":"Chief of Staff, Chief HR Officer & Director"},{"age":null,"name":"Mr. Jason  Jaingue","title":"Head of Global Product"}],"industry":"Education & Training Services","irWebsite":"","website":"https://www.geniusgroup.net","phone":"65 6950 3859"}}